Answers are grounded in this paper and cite their sources.
Proposes that cerumen tau is a non-invasive biomarker for Alzheimer's, linking hearing loss and neurodegeneration.
This paper proposes that cochlear hair cell death and Alzheimer's disease (AD)-associated neurodegeneration share a common upstream cause in systemic membrane lipid dysregulation, providing a mechanistically distinct explanation for the established hearing loss-AD association beyond the cognitive stimulation hypothesis. Hearing loss is one of the strongest modifiable risk factors for AD, preceding dementia onset by 5-10 years; the prevailing explanation that auditory deprivation reduces cognitive stimulation likely contributes but cannot fully account for the robustness of this association. The primary hypothesis is that otoacoustic emission (OAE) amplitude decline rate, plasma PE/PC ratio, and pTau181 form a correlated biomarker cluster tracking the same upstream lipid pathology, with OAE decline as the earliest accessible signal. While the individual components of the proposed panel have been studied in isolation, this is the first proposal to link them mechanistically through shared lipid membrane pathology, motivated by the TMC1/TMC2 scramblase finding (Lee, Park, & Ballesteros, 2026). The mechanistic chain operates as follows. Recent NIDCD work identifies TMC1 and TMC2, cochlear mechanotransduction proteins, as lipid scramblases whose activity is directly regulated by membrane cholesterol. When membrane lipid composition is disrupted (specifically PE and PC depletion, documented in AD brain and plasma), TMC1/TMC2 scramblase gating fails, phosphatidylserine is externalized, and hair cells undergo irreversible apoptosis. Because hair cells are terminally differentiated and non-regenerating, this loss is detectable early via OAEs, before subjective hearing loss and potentially before CNS tau pathology is measurable. A secondary contribution is the proposal of cerumen (earwax) tau as a non-invasive CNS-adjacent biomarker (Section 4). Cerumen is produced by modified apocrine glands in anatomical proximity to the cochlea and contains exfoliated epithelial cells and extracellular vesicles. If cochlear hair cell stress or apoptosis produces detectable tau species (consistent with what occurs in CNS neurodegeneration), cerumen would provide a zero-burden, non-invasive sampling route to cochlear and CNS-adjacent tau burden without blood draw or lumbar puncture. **Keywords:** Alzheimer's disease; cerumen; tau biomarker; pTau181; TMC1; TMC2; lipid scramblase; cochlear hair cell; otoacoustic emissions; phosphatidylethanolamine; phosphatidylcholine; PE/PC ratio; hearing loss; non-invasive biomarker; APOE ε4; extracellular vesicles; aminoglycoside; shared lipid pathology; zero-burden sampling
No takes yet. Share an insight, caveat, or question.
Arthur Stewart (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: